News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Johnson & Johnson has announced its intent to separate its Consumer Health business into a new publicly traded company: allowing J&J to put a sharpened focus on pharmaceuticals and medical devices.
Be the Match BioTherapies (BTMB) says it is critical that resilient cell sourcing infrastructures exist when cell and gene therapies (CGT) surge to market.
Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, recently announced an $80m Series B round, taking the funds it has raised to date to $100m+.